Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry
Mankind Pharma Ltd · Investor Presentation · 27 Oct 2026, 10:44 pm
Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry Mankind Pharma reported FY26 revenue of ₹14,278 Cr, posting an 18.1% CAGR over FY21–26. As of Q2 FY27, volume growth reached 6.2% versus IPM's 5.2%. The company aims to expand its chronic portfolio from ~39% to ~50% of sales by FY30E and scale hospital sales to ~5%. Outstanding debt fell ~75% from peak levels to ~₹2,500 Cr, with full repayment targeted by 2028. Additionally, Mankind acquired a 70% stake in Belgium-based Armed Cell Therapeutics for €48 Mn to advance in-vivo CAR-T oncology candidates.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA · 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference · 06 Nov 2026
- Please find attached intimation regarding ESG Rating · 05 Nov 2026
- Intimation of participation in the Investor Conference. · 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 · 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL · 30 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 · 27 Oct 2026
- Investor Presentation on Financial Results of the Company for Q2 & H1FY27 · 26 Oct 2026
